NCT07742098Not yet recruitingPhase 2
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Domain Within the ACT-GLOBAL Trial Platform, to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 27 Jul 2026
- Start date
- 31 Oct 2026
- Primary completion date
- 15 Dec 2028
- Lead sponsor
- NeuroTrauma Sciences, LLC
- Diseases
- Stroke
- NCT number
- NCT07742098
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 140
- From 31 Oct 2026 to the primary completion date, 15 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pre-existing motor deficit prior to index stroke
- Recent major surgery or trauma (\<30 days)
Other illness
- Posterior circulation ischemic stroke
- Lacunar stroke
- Qualifying brain imaging demonstrating intracranial hemorrhage, malignant middle cerebral artery (MCA) infarct with edema, or bilateral/multifocal infarcts, clinically significant vascular malformation, brain tumor, or other central nervous system (CNS) pathology
Who the study is looking for
- Acute ischemic stroke with moderate to severe hemiparesis
- Functional independence in activities of daily living without requiring nursing care before the index stroke.
- Consent process by participant or proxy, with reconsent provision.
- Age ≥ 45 to ≤ 80 years of age (inclusive) on the date of randomization
- Sufficient attention, comprehension, and cooperation to carry out instructions
Age in the registry: 45 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.